AUTHOR=He Xiaobo , Cheng Xiao , Feng Xudong , Wan Hong , Chen Sihan , Xiong Maoming 

TITLE=Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis

JOURNAL=Frontiers in Public Health

VOLUME=8

YEAR=2021

URL=https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2020.561264

DOI=10.3389/fpubh.2020.561264

ISSN=2296-2565

ABSTRACT=<p><bold>Objective:</bold> The prognosis of mild and severe patients has prominent differences during the prevalence of COVID-19, and it will be significant to identify patients' potential risk of progressing to severe cases according to their first clinical presentations. Therefore, we aim to review the clinical symptoms of the COVID-19 epidemic systematically.</p><p><bold>Methods:</bold>We searched PubMed, Embase, Web of Science, and CNKI (Chinese Database) for studies about the clinical features of COVID-19 in China from March 18 to April 18. Then we used REVMAN to conduct a meta-analysis.</p><p><bold>Results:</bold> After screening, 20 articles including 3,326 COVID-19 confirmed cases were selected from 142 articles we retrieved at the beginning of our research. We divided all the cases into a severe group (including severe and critically severe patients) and a mild group according to the “Diagnosis and Treatment Protocol for Novel Coronavirus Infection-Induced Pneumonia” version 4 (trial). Of all the initial symptoms (including fever, cough, abdominal pain, anorexia, chest tightness, diarrhea, dyspnea, expectoration, fatigue, headache, hemoptysis, myalgia, nausea or vomiting, and pharyngalgia) we studied, we found that cough (odds ratio [OR] = 1.4, 95% confidence interval [CI]: 1.2–1.7; <italic>p</italic> &lt; 0.001), fever (OR = 1.5, 95% CI: 1.2–1.9; <italic>p</italic> &lt; 0.001), dyspnea (OR = 6.2, 95% CI: 3.6–10.6; <italic>p</italic> &lt; 0.001), diarrhea (OR = 2.6, 95% CI: 1.3–4.9; <italic>p</italic> &lt; 0.001), fatigue (OR = 2.1, 95% CI: 1.3–3.3; <italic>p</italic> &lt; 0.01), expectoration (OR = 1.7, 95% CI: 1.2–2.6; <italic>p</italic> &lt; 0.01), myalgia (OR = 1.6, 95% CI: 0.8–3.1; <italic>p</italic> &lt; 0.001), hemoptysis (OR = 4.0, 95% CI: 1.5–11.3; <italic>p</italic> &lt; 0.001), abdominal pain (OR = 7.5, 95% CI: 2.4–23.4; <italic>p</italic> &lt; 0.001), and anorexia (OR = 2.8, 95% CI: 1.5–5.1; <italic>p</italic> &lt; 0.001) had a different distribution in two groups and were statistically significant (<italic>p</italic> &lt; 0.05).</p><p><bold>Conclusion:</bold>COVID-19 patients whose initial manifestation is dyspnea, hemoptysis, anorexia, diarrhea, or fatigue, especially abdominal pain should be closely monitored to prevent disease deterioration.</p>